Current Report Filing (8-k)
26 Februar 2013 - 7:02PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event
reported): February 26, 2013
BIOMIMETIC THERAPEUTICS, INC.
(Exact Name of Registrant as Specified
in Charter)
Delaware |
000-51934 |
62-1786244 |
(State or Other Jurisdiction
of Incorporation) |
(Commission File Number) |
(I.R.S. Employer
Identification No.) |
389 Nichol Mill Lane, Franklin, Tennessee
37067
(Address of Principal Executive Offices)
(Zip Code)
(615) 844-1280
(Registrant’s telephone number,
including area code)
Not Applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| | |
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.07 Submission of Matters to a
Vote of Security Holders
On February 26, 2013,
BioMimetic Therapeutics, Inc. (“BioMimetic”) held a special meeting of its stockholders (the “Special Meeting”).
Two proposals were voted on at the meeting: (1) to adopt the Agreement and Plan of Merger, dated November 19, 2012, by and among
Wright Medical Group, Inc., Achilles Merger Subsidiary, Inc., Achilles Acquisition Subsidiary, LLC and BioMimetic, pursuant to
which Achilles Merger Subsidiary, Inc. will be merged with and into BioMimetic and immediately thereafter, BioMimetic will merge
with and into Achilles Acquisition Subsidiary, LLC as described in the definitive proxy statement first mailed to the stockholders
of BioMimetic on or about January 23, 2013 (the “Proxy Statement”); and (2) to approve, on an advisory (non-binding)
basis, the “golden parachute” compensation payments that will or may be paid by BioMimetic to its named executive officers
in connection with the merger as described in the Proxy Statement.
Stockholders of
record at the close of business on January 2, 2013 were entitled to vote at the Special Meeting. As of January 2, 2013, there
were 28,264,814 shares of common stock outstanding and entitled to vote. A quorum consisting of 14,132,408 shares of common
stock of BioMimetic were present or represented at the meeting.
All of the proposals
requiring approval were approved by the requisite vote necessary, and the votes with respect to each of the proposals are set forth
below:
| (1) | To adopt the Agreement and Plan of Merger, dated November 19, 2012, by and among Wright Medical
Group, Inc., Achilles Merger Subsidiary, Inc., Achilles Acquisition Subsidiary, LLC and BioMimetic: |
For |
|
Against |
|
Abstain |
|
|
|
|
|
|
|
19,899,622 |
|
175,108 |
|
26,780 |
|
| (2) | To approve, on an advisory (non-binding) basis, the “golden parachute” compensation payments that will or may be
paid by BioMimetic to its named executive officers in connection with the merger: |
For |
|
Against |
|
Abstain |
|
|
|
|
|
|
|
18,132,287 |
|
1,909,948 |
|
59,275 |
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
BIOMIMETIC THERAPEUTICS, INC. |
|
|
|
By: |
/s/ Larry Bullock |
|
|
Name: Larry Bullock |
|
|
Title: Chief Financial Officer |
Date: February 26, 2013
Biomimetic Therapeutics, Inc. (MM) (NASDAQ:BMTI)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Biomimetic Therapeutics, Inc. (MM) (NASDAQ:BMTI)
Historical Stock Chart
Von Jun 2023 bis Jun 2024